McKesson Board Can't Dodge Opioid Shipment `Red Flags' Suit
- Directors accused of failing to monitor suspicious drug orders
- Judge allows investors to press executive compensation claims
This article is for subscribers only.
Some McKesson Corp. directors must face an investor lawsuit accusing them of failing to honor promises to ensure internal systems for spotting suspicious opioid shipments functioned properly.
Two shareholders of the San Francisco-based company can press claims the distributor’s board was asleep at the switch when it came to overseeing such shipments after a 2008 settlement spawned by the firm’s inept monitoring of the painkillers, a federal judge in Oakland, California, ruled.